Accession Number
Small Molecule

Tinzaparin is a low molecular weight heparin (LMWH), produced by enzymatic depolymerization of unfractionated heparin from porcine intestinal mucosa. It is a heterogeneous mixture of with an average molecular weight between 5500 and 7500 daltons. Tinzaparin is composed of molecules with and without a special site for high affinity binding to antithrombin III (ATIII). This complex greatly accelerates the inhibition of factor Xa. It is an anticoagulant and considered an antithrombotic. Tinzaparin must be given either subcutaneously or parenterally. LMWHs are less effective at inactivating factor IIa due to their shorter length compared to unfractionated heparin.

  • Tinzaparin sodium
  • Tinzaparina
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
InnohepSolution20000 unitSubcutaneousLeo Pharma1997-09-23Not applicableCanada
InnohepSolution10000 unitSubcutaneousLeo Pharma1997-07-31Not applicableCanada
InnohepSolution20000 unitSubcutaneousLeo Pharma1997-02-28Not applicableCanada
InnohepSolution10000 unitSubcutaneousLeo Pharma1995-12-31Not applicableCanada
InnohepInjection, solution20000 [iU]/1mLSubcutaneousLeo Pharma2010-07-012013-08-01Us
InnohepSolution12000 unitSubcutaneousLeo Pharma2014-09-30Not applicableCanada
InnohepInjection20000 [iU]/1mLSubcutaneousCelgene2008-04-14Not applicableUs
InnohepSolution8000 unitSubcutaneousLeo Pharma2014-09-30Not applicableCanada
InnohepSolution20000 unitSubcutaneousLeo Pharma2011-09-13Not applicableCanada
InnohepSolution10000 unitSubcutaneousLeo Pharma2011-12-10Not applicableCanada
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
CAS number



Tinzaparin is used for the prevention of postoperative venous thromboembolism in patients undergoing orthopedic surgery and in patients undergoing general surgery who are at high risk of developing postoperative venous thromboembolism. It is also used for the treatment of deep vein thrombosis and/or pulmonary embolism. It is indicated for use in preventing clot formation in indwelling intravenous lines for hemodialysis.

Associated Conditions

Tinzaparin, like other LMWHs, have a higher anti-Xa activity than anti-IIa activity. The anti-Xa activity of tinzaparin is 2.0 +/- 0.5 times greater than its to anti-IIa activity. Heparin exhibits approximately equal inhibitory activity against Xa and IIa. Tinzaparin is an anticoagulant that blocks the formation of thrombi. Like all LMWHs, tinzaparin only causes activated partial thromboplastin time (aPTT) prolongation at higher doses and routine monitoring is not recommended. However, anti-factor Xa levels may be monitored in some conditions such as pregnancy and renal dysfunction. Its use should be avoided in patients with a creatinine clearance less than 20 mL/min. In these patients, unfractionated heparin should be used. Tinzaparin can be used in patients who have a creatinine clearance between 20-30 mL/min, giving it the highest safety threshold for use in renal failure patients compared to all the LMWHs.

Mechanism of action

Tinzaparin binds to the plasma protein antithrombin III, forming a complex with then accelerates the inhibition of factor Xa. Its affinity for factor Xa is 2-4 times greater than that of unbound ATIII. The inactivation of factor Xa in turn will exponentially generation of thrombin (factor IIa) molecules, which is needed to activate fibrinogen to fibrin. The coagulation cascade is inhibited because fibrin cannot be formed in the presence of tinzaparin. Like all LMWH, it cannot be given intramuscularly due to increased risk of hematoma.

UIntegrin alpha-4
UStromal cell-derived factor 1
Additional Data Available
Adverse Effects

Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.

Learn more
Additional Data Available

Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.

Learn more
Additional Data Available
Blackbox Warnings

Structured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.

Learn more

Subcutaneous injection - about 90% when measured as anti-Xa activity versus 67% for anti-IIa activity.

Volume of distribution

Anti-Xa activity is 4 L. Anti-IIa activity is 10.9 L

Protein binding

Low protein binding compared to unfractionated heparin.


Sulfation and polymerization occurs in the liver.

Route of elimination

Linear elimination through kidneys

Half life

Anti-Xa activity is 82 minutes. Anti-IIa activity is 71 minutes.


Clearance is dose-dependant. The clearance of tinzaparin based on anti-Xa activity ranged from 1.14 to 2.04 L/hr


Osteoporosis with increasing duration of use, bleeding, alopecia, heparin induced thrombocytopenia (HIT). All of these adverse drug reactions occur less with LMWH compared to unfractionated heparin. Tinzaparin showed no toxic effects at doses up to 5 mg/kg in mice, rats, or dogs in standard acute, subacute, and chronic toxicity studies.

Affected organisms
Not Available
Not Available
Pharmacogenomic Effects/ADRs
Not Available


Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
(1,2,6,7-3H)Testosterone(1,2,6,7-3H)Testosterone may increase the anticoagulant activities of Tinzaparin.
(R)-warfarinThe risk or severity of bleeding can be increased when Tinzaparin is combined with (R)-warfarin.
(S)-WarfarinThe risk or severity of bleeding can be increased when Tinzaparin is combined with (S)-Warfarin.
1-Testosterone1-Testosterone may increase the anticoagulant activities of Tinzaparin.
18-methyl-19-nortestosterone18-methyl-19-nortestosterone may increase the anticoagulant activities of Tinzaparin.
3,5-Diiodotyrosine3,5-Diiodotyrosine may increase the anticoagulant activities of Tinzaparin.
4-hydroxycoumarinThe risk or severity of bleeding can be increased when Tinzaparin is combined with 4-hydroxycoumarin.
4-Hydroxytestosterone4-Hydroxytestosterone may increase the anticoagulant activities of Tinzaparin.
5beta-dihydrotestosterone5beta-dihydrotestosterone may increase the anticoagulant activities of Tinzaparin.
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineThe risk or severity of bleeding and hemorrhage can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Tinzaparin.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
  • Avoid herbs and supplements with anticoagulant/antiplatelet activity. Examples include ginger, ginkgo, and garlic.


General References
  1. Friedel HA, Balfour JA: Tinzaparin. A review of its pharmacology and clinical potential in the prevention and treatment of thromboembolic disorders. Drugs. 1994 Oct;48(4):638-60. [PubMed:7528134]
  2. Simonneau G, Sors H, Charbonnier B, Page Y, Laaban JP, Azarian R, Laurent M, Hirsch JL, Ferrari E, Bosson JL, Mottier D, Beau B: A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou Heparine Standard: Evaluations dans l'Embolie Pulmonaire. N Engl J Med. 1997 Sep 4;337(10):663-9. [PubMed:9278462]
  3. Planes A, Samama MM, Lensing AW, Buller HR, Barre J, Vochelle N, Beau B: Prevention of deep vein thrombosis after hip replacement--comparison between two low-molecular heparins, tinzaparin and enoxaparin. Thromb Haemost. 1999 Jan;81(1):22-5. [PubMed:10348714]
  4. Cheer SM, Dunn CJ, Foster R: Tinzaparin sodium: a review of its pharmacology and clinical use in the prophylaxis and treatment of thromboembolic disease. Drugs. 2004;64(13):1479-502. [PubMed:15212562]
  5. Hoy SM, Scott LJ, Plosker GL: Tinzaparin sodium: a review of its use in the prevention and treatment of deep vein thrombosis and pulmonary embolism, and in the prevention of clotting in the extracorporeal circuit during haemodialysis. Drugs. 2010 Jul 9;70(10):1319-47. doi: 10.2165/11203710-000000000-00000. [PubMed:20568836]
  6. Hedner U: Development of tinzaparin: a heparinase-digested low-molecular-weight heparin. Semin Thromb Hemost. 2000;26 Suppl 1:23-9. [PubMed:11011803]
  7. Pautas E, Siguret V, d'Urso M, Laurent M, Gaussem P, Fevrier M, Durand-Gasselin B: [Monitoring of tinzaparin in a ten day treatment dose in elderly patients]. Rev Med Interne. 2001 Feb;22(2):120-6. [PubMed:11234669]
  8. Pineo GF, Hull RD: Tinzaparin in the treatment of venous thromboembolism. Expert Opin Pharmacother. 2003 Dec;4(12):2355-62. [PubMed:14640933]
  9. Fossler MJ, Barrett JS, Hainer JW, Riddle JG, Ostergaard P, van der Elst E, Sprogel P: Pharmacodynamics of intravenous and subcutaneous tinzaparin and heparin in healthy volunteers. Am J Health Syst Pharm. 2001 Sep 1;58(17):1614-21. [PubMed:11556655]
  10. Cambus JP, Saivin S, Heilmann JJ, Caplain H, Boneu B, Houin G: The pharmacodynamics of tinzaparin in healthy volunteers. Br J Haematol. 2002 Mar;116(3):649-52. [PubMed:11849226]
External Links
PubChem Substance
ATC Codes
B01AB10 — Tinzaparin
AHFS Codes
  • 20:12.04.16 — Heparins

Clinical Trials

Clinical Trials
0TerminatedTreatmentAntiphospholipid Syndrome in Pregnancy / Pregnancy Loss1
1, 2Unknown StatusTreatmentRenal Cancers1
2CompletedBasic ScienceMalignant Lymphomas / Multiple Myeloma (MM)1
2CompletedTreatmentStroke, Ischemic1
2Not Yet RecruitingTreatmentCOVID19 Pneumonia / Novel Coronavirus Infectious Disease (COVID-19)1
2RecruitingTreatmentCerebral Venous Thrombosis1
2TerminatedPreventionMalignancies / Venous Thromboembolism1
2TerminatedSupportive CareDeep Vein Thrombosis / Malignancies / Pulmonary Embolism / Thrombotic events / Venous Thromboembolism1
2, 3CompletedPreventionDeep Vein Thrombosis1
2, 3CompletedPreventionHemodialysis Treatment / Thromboembolism1
3CompletedTreatmentDeep Venous Thrombosis1
3CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Lung Cancers1
3CompletedTreatmentVenous Thromboembolism1
3RecruitingPreventionAdenocarcinoma of the Colon1
3RecruitingPreventionNeoplasms, Lung / Venous Thromboembolism1
3RecruitingTreatmentAcute Chest Syndrome / Anemia / Low-Molecular-Weight Heparin / Sickle Cell1
3RecruitingTreatmentDeep Vein Thrombosis / Pulmonary Embolism / Venous Thromboembolism1
3TerminatedTreatmentNeoplasms / Venous Thromboembolism1
4CompletedNot AvailableVenous Thromboembolism1
4CompletedPreventionChronic Renal Failure (CRF)1
4CompletedTreatmentAcute Pulmonary Embolism1
4CompletedTreatmentDeep Vein Thrombosis1
4CompletedTreatmentIntrauterine Growth Retardation1
4CompletedTreatmentThromboembolism / Thrombosis, Venous / Thrombotic events2
4CompletedTreatmentVenous Thromboembolism1
4RecruitingPreventionCOVID / Deep Vein Thrombosis / Novel Coronavirus Infectious Disease (COVID-19) / Pulmonary Embolism / Thrombotic events1
4RecruitingPreventionDeep Venous Thrombosis / Pulmonary Embolism1
4RecruitingSupportive CareAcute Kidney Injury (AKI) / Anticoagulants / Renal Replacement Therapies1
4RecruitingTreatmentArterial Occlusion1
4WithdrawnPreventionDiabetes Mellitus / Hemodialysis Treatment1
Not AvailableCompletedNot AvailableDeep Venous Thrombosis, Protection Against / Renal Insufficiency,Chronic1
Not AvailableCompletedNot AvailableUnsuspected Pulmonary Embolism1
Not AvailableCompletedNot AvailableVenous Thromboembolism1
Not AvailableCompletedPreventionDeep Vein Thrombosis / Malignancies / Pulmonary Embolism1
Not AvailableCompletedPreventionPrimary Brain Tumors1
Not AvailableTerminatedNot AvailableInflammatory Reaction / Nutrition / Peritoneal dialysis therapy1
Not AvailableTerminatedTreatmentPulmonary Embolism / Thrombosis, Venous1
Not AvailableUnknown StatusNot AvailableBleeding / Venous Thromboembolism1
Not AvailableUnknown StatusNot AvailablePositive Anti Phospholipid Syndrome / Recurrent Pregnancy Losses1


Not Available
Not Available
Dosage forms
InjectionSubcutaneous20000 [iU]/1mL
Injection, solutionSubcutaneous20000 [iU]/1mL
SolutionSubcutaneous10000 unit
SolutionSubcutaneous12000 unit
SolutionSubcutaneous16000 unit
SolutionSubcutaneous20000 unit
SolutionSubcutaneous8000 unit
Not Available
Not Available


Experimental Properties
Not Available
Predicted Properties
Not Available
Predicted ADMET features
Not Available


Mass Spec (NIST)
Not Available
Not Available


Not classified


Pharmacological action
General Function
Serine-type endopeptidase inhibitor activity
Specific Function
Most important serine protease inhibitor in plasma that regulates the blood coagulation cascade. AT-III inhibits thrombin, matriptase-3/TMPRSS7, as well as factors IXa, Xa and XIa. Its inhibitory a...
Gene Name
Uniprot ID
Uniprot Name
Molecular Weight
52601.935 Da
  1. Bisio A, Vecchietti D, Citterio L, Guerrini M, Raman R, Bertini S, Eisele G, Naggi A, Sasisekharan R, Torri G: Structural features of low-molecular-weight heparins affecting their affinity to antithrombin. Thromb Haemost. 2009 Nov;102(5):865-73. doi: 10.1160/TH09-02-0081. [PubMed:19888521]
  2. Florian-Kujawski M, Hoppensteadt D, Maddineni J, Ziegler H, Fareed J: Differential regulation of thrombin activatable fibrinolytic inhibitor by low molecular weight heparins. Pharmacologic implications. Int Angiol. 2004 Dec;23(4):346-54. [PubMed:15767980]
  3. Morris TA, Jacobson A, Marsh JJ, Lane JR: Pharmacokinetics of UH and LMWH are similar with respect to antithrombin activity. Thromb Res. 2005;115(1-2):45-51. [PubMed:15567452]
Pharmacological action
General Function
Metal ion binding
Specific Function
Integrins alpha-4/beta-1 (VLA-4) and alpha-4/beta-7 are receptors for fibronectin. They recognize one or more domains within the alternatively spliced CS-1 and CS-5 regions of fibronectin. They are...
Gene Name
Uniprot ID
Uniprot Name
Integrin alpha-4
Molecular Weight
114898.745 Da
  1. Schlesinger M, Simonis D, Schmitz P, Fritzsche J, Bendas G: Binding between heparin and the integrin VLA-4. Thromb Haemost. 2009 Nov;102(5):816-22. doi: 10.1160/TH09-01-0061. [PubMed:19888514]
Pharmacological action
General Function
Not Available
Specific Function
Not Available
Gene Name
Uniprot ID
Uniprot Name
Stromal cell-derived factor 1
Molecular Weight
10665.75 Da
  1. Koo CY, Sen YP, Bay BH, Yip GW: Targeting heparan sulfate proteoglycans in breast cancer treatment. Recent Pat Anticancer Drug Discov. 2008 Nov;3(3):151-8. [PubMed:18991783]


Pharmacological action
General Function
Zinc ion binding
Specific Function
Cleaves aggrecan, a cartilage proteoglycan, and may be involved in its turnover. May play an important role in the destruction of aggrecan in arthritic diseases. Could also be a critical factor in ...
Gene Name
Uniprot ID
Uniprot Name
A disintegrin and metalloproteinase with thrombospondin motifs 4
Molecular Weight
90196.02 Da
  1. Mousa SA: Effect of low molecular weight heparin and different heparin molecular weight fractions on the activity of the matrix-degrading enzyme aggrecanase: structure-function relationship. J Cell Biochem. 2005 May 1;95(1):95-8. [PubMed:15723278]

Drug created on September 14, 2010 10:21 / Updated on May 25, 2020 23:43

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.